DDX17 and cardiac hypertrophy: Previous studies have shown that DDX17 can inhibit doxorubicin-induced cardiomyocyte injury in vitro and is involved in the pathogenesis of cardiac hypertrophy by regulating the expression of the long non-coding RNA cardiac physiological hypertrophy-associated regulator.6,7 Although DDX17 is highly expressed in cardiomyocytes, the function of DDX17 in the cardiovascular system, particularly in the development of heart failure, is still not fully understood.